Mergers and Acquisitions in the biopharma space continue to heat up, fueling a significant increase in large deals through the first 9…
McAlinden Research PartnersOctober 19, 2022
A decade after its discovery, an authorization of CRISPR drugs to be marketed in the US may only be a…
McAlinden Research PartnersJuly 11, 2022
Despite a prolonged sell-off in biotech stocks, the development of genomic medicine has continued apace. For just the third time,…
McAlinden Research PartnersMay 23, 2022
Research into CRISPR gene editing technology continues to expand the amount of potential applications, while shrinking the actual size of proteins…
McAlinden Research PartnersSeptember 8, 2021
Promising developments in new gene editing trials continue to drive investor interest in the growing biotech sector. Potential advancements include the…
McAlinden Research PartnersJuly 22, 2021
Gene editing trials continue to heat up, as more and more labs initiate testing on humans. Genomics is increasingly popular among…
McAlinden Research PartnersFebruary 4, 2021
A wealth of new data from several leading genomics firms have launched stocks in the sector higher in the fourth…
McAlinden Research PartnersDecember 22, 2020
New developments in advanced methods of CRISPR, particularly in base and prime editing, continue to propel the popularity of the…
McAlinden Research PartnersSeptember 1, 2020
Treatments utilizing Clustered Regularly Interspace Short Palindromic Repeats (CRISPR), continue to rack up clinical success. The latest research on blood…
McAlinden Research PartnersJune 16, 2020
